AKTX Akari Therapeutics PLC ADRs

Akari Therapeutics PLC is a biopharmaceutical company in clinical stage. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$0.94
As of 07/01/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  05/07/2013
Outstanding shares:  59,349,171
Average volume:  47,731
Market cap:   $56,381,712
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   5.22
PS ratio:   0.00
Return on equity:   -171.10%
Net income %:   0.00%